Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind adjuvant Herceptin vs TX05 in HER2-positive early breast cancer (extension of TX05-03)
2018-000236-97Phase 3Completed
- Sponsor
- Tanvex BioPharma
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Adjuvant Herceptin with Adjuvant TX05 (2 arms). Primary endpoints: Safety and Immunogenicity. Started May 2018; status: completed.
02
Drugs
trastuzumabTrastuRel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-000236-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000236-97.